About Exact Sciences
Exact Sciences is a company based in Madison (United States) founded in 1995 was acquired by Abbott in March 2026. The company has 7,000 employees as of December 31, 2024. Exact Sciences has completed 12 acquisitions, including Armune, Base Genomics and Biomatrica. Exact Sciences operates in a competitive market with competitors including BridgeBio, Guardant Health, Spark Therapeutics, Natera and Alnylam, among others.
- Headquarter Madison, United States
- Employees 7000 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Exact Sciences Corporation
-
Annual Revenue
$2.76 B (USD)10.37as on Dec 31, 2024
-
Net Profit
-$1.03 B (USD)-403.97as on Dec 31, 2024
-
EBITDA
$23.07 M (USD)130.21as on Dec 31, 2024
-
Latest Funding Round
$747.5 M (USD), Post-IPO
Mar 08, 2019
-
Investors
Abbott
& 1 more
-
Employee Count
7000
as on Dec 31, 2024
-
Investments & Acquisitions
Armune
& 11 more
-
Acquired by
Abbott
(Mar 20, 2026)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Exact Sciences
Exact Sciences is a publicly listed company on the NASDAQ with ticker symbol EXAS in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of Exact Sciences
Unlock access to complete
Unlock access to complete
Leadership Team
105 people
Software Development Team
103 people
Screening Team
78 people
Senior Team
62 people
Sales and Marketing
30 people
Data Analysis and Operations Team
29 people
Human Resources and Administration
28 people
Operations Team
23 people
Unlock access to complete
Funding Insights of Exact Sciences
Investors in Exact Sciences
Exact Sciences has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Abbott and Bank of America.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Commercial banking and asset management services are offered worldwide.
|
Locked | Locked | Locked | |
|
Developer of medical devices, generic pharmaceuticals, and nutrition products
|
Locked | Locked | Locked |
Investor details for Exact Sciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Exact Sciences
Exact Sciences has strategically engaged in corporate development activities, having acquired 12 companies. Notable acquisitions include Armune, Base Genomics and Biomatrica.
Investment portfolio details for Exact Sciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
In-vitro DNA methylation tests for early cancer detection are offered.
|
Locked | Locked | 2019 | Locked | |
|
Tools for protein data analysis are provided by OmicEra Diagnostics.
|
Locked | Locked | 2019 | Locked | |
|
Blood-based liquid biopsy tests for multiple cancer detection are provided.
|
Locked | Locked | 2019 | Locked |
Complete acquisition details for Exact Sciences
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Exact Sciences
Detailed financials for Exact Sciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Exact Sciences Comparisons
Peer comparison for Exact Sciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Exact Sciences
Exact Sciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Guardant Health, Spark Therapeutics, Natera and Alnylam, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Digital sequencing technology for cancer detection is developed.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
Developer of cell-free DNA testing for oncology, women’s health, and organ health
|
|
| Locked | Locked | Locked |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
Detailed competitors of Exact Sciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Exact Sciences
Complete news archive for Exact Sciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Exact Sciences
Exact Sciences was founded in 1995 and raised its 1st funding round 14 years after it was founded.
Exact Sciences is headquartered in Madison, United States. It is registered at Madison, Wisconsin, United States.
Kevin Conroy is the current CEO of Exact Sciences.
As of Dec 31, 2024, the latest employee count at Exact Sciences is 7,000.
Annual revenue of Exact Sciences is $2.76B as on Dec 31, 2024.
Provider of non-invasive molecular diagnostic testing solutions for cancer. The flagship product includes Cologuard is intended for the qualitative detection of colorectal neoplasia-associated DNA markers and for the presence of occult hemoglobin in human stool to estimate a patients risk of developing colorectal cancer. Also, it offers an MCED blood test for multi-cancer detection.
Exact Sciences's top competitors include Guardant Health, Spark Therapeutics and BridgeBio.
Yes, Exact Sciences is publicly traded on NASDAQ under the ticker symbol EXAS.
Exact Sciences has made 12 acquisitions, including Armune, Base Genomics, and Biomatrica.
Exact Sciences has 2 investors. Key investors include Abbott, and Bank of America.
The ticker symbol of Exact Sciences is EXAS on NASDAQ.